Dicerna Pharmaceuticals, Inc. (DRNA) financial statements (2020 and earlier)

Company profile

Business Address 33 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments349303114469596
Cash and cash equivalents1535469215626
Short-term investments19624845253970
Receivables200100    
Prepaid expense111011
Other current assets00   0
Other undisclosed current assets624200
Total current assets:556406119489697
Noncurrent Assets
Operating lease, right-of-use asset30
Property, plant and equipment732232
Long-term investments and receivables     3
Long-term investments     3
Restricted cash and investments411111
Other noncurrent assets000000
Total noncurrent assets:4142346
TOTAL ASSETS:59740912151100104
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16119891
Accounts payable655431
Accrued liabilities22214 
Employee-related liabilities74222 
Deferred revenue212
Debt3     
Estimated litigation liability 11    
Deferred revenue and credits6 00
Contract with customer, liability69
Other undisclosed current liabilities10422 4
Total current liabilities:24294171095
Noncurrent Liabilities
Long-term debt and lease obligation20     
Operating lease, liability20
Liabilities, other than long-term debt1831143   
Deferred revenue and credits3   
Deferred revenue183
Contract with customer, liability114
Other liabilities1     
Other undisclosed noncurrent liabilities     0
Total noncurrent liabilities:2031143  0
Total liabilities:445208201095
Stockholders' equity
Stockholders' equity attributable to parent152201101419198
Common stock000000
Additional paid in capital678605417297287232
Accumulated deficit(525)(405)(316)(256)(196)(133)
Total stockholders' equity:152201101419198
TOTAL LIABILITIES AND EQUITY:59740912151100104

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net1   
Gross profit:246200 
Operating expenses(152)(97)(63)(60)(63)(45)
Operating loss:(128)(90)(61)(60)(63)(45)
Nonoperating income (expense)81100(3)
Investment income, nonoperating821000
Interest and debt expense(0)(1)   (0)
Loss from continuing operations before income taxes:(120)(89)(60)(60)(63)(48)
Income tax expense     (0)
Other undisclosed income from continuing operations     3
Net loss:(120)(89)(60)(60)(63)(45)
Other undisclosed net income (loss) attributable to parent01   (3)
Net loss attributable to parent:(120)(89)(60)(60)(63)(48)
Preferred stock dividends and other adjustments  (16)  (0)
Other undisclosed net loss available to common stockholders, basic  (4)   
Net loss available to common stockholders, diluted:(120)(89)(80)(60)(63)(48)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(120)(89)(60)(60)(63)(45)
Comprehensive loss, net of tax, attributable to parent:(120)(89)(60)(60)(63)(45)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: